Intensity Therapeutics Secures $6.6 Million to Advance Cancer Treatment Research

Intensity Therapeutics, Inc., a biotechnology company specializing in late-stage clinical research, has announced the successful acquisition of $6.6 million in gross proceeds from at-the-market (ATM) stock sales in July 2025. This financial injection is earmarked for the continuation and expansion of clinical trials, particularly for the company's leading investigational product, INT230-6, which is poised to transform cancer treatment methodologies.

The company executed the sale of 19,868,658 shares of its common stock at an average price of $0.3323 per share, culminating in net proceeds of approximately $6.3 million. This strategic financial maneuver not only bolsters Intensity Therapeutics' financial standing but also secures the capital required to propel its clinical trials well into the second half of 2026. Lewis H. Bender, the President and CEO of Intensity, emphasized the advantageous market conditions that facilitated this achievement, noting the company's ability to leverage strong liquidity to secure a higher average price per share than its public offering in June 2025.

INT230-6 stands at the forefront of Intensity Therapeutics' research efforts, embodying a novel cancer therapy approach. This product is engineered for direct intratumoral injection, integrating two powerful anti-cancer agents with a distinctive diffusion enhancer to precisely target tumors while reducing systemic side effects. Preliminary results suggest that INT230-6 not only effectively destroys tumors but also activates the immune system to identify and fight cancer, potentially revolutionizing treatment strategies.

Currently, Intensity Therapeutics is conducting several clinical trials, including a Phase 3 trial focused on soft tissue sarcoma and a Phase 2 study targeting triple-negative breast cancer. These initiatives position the company as a leader in the development of treatments that could convert lethal cancers into manageable diseases. The recent financial milestone and the innovative nature of its research underscore Intensity Therapeutics' dedication to pioneering advancements in cancer therapy and enhancing patient care. For further details on Intensity Therapeutics and its cutting-edge research, visit https://www.intensitytherapeutics.com.